Vitamin D receptor expression and neoadjuvant therapy in esophageal adenocarcinoma

Ryan Trowbridge; Poonam Sharma; William J. Hunter; Devendra K. Agrawal

doi:10.1016/j.yexmp.2012.04.018

Vitamin D receptor expression and neoadjuvant therapy in esophageal adenocarcinoma

Ryan Trowbridge, Poonam Sharma, William J. Hunter, Devendra K. Agrawal

Department of Pathology

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Abstract

Esophageal adenocarcinoma carries a poor prognosis. Tumor response to neoadjuvant therapy is a key prognostic factor in patients with adenocarcinoma of the esophagus, but is inconsistent. Identifying tumor characteristics that portend a favorable response to neoadjuvant therapy would be a valuable clinical tool. The anticancer actions of vitamin D and its receptor may have implications. In this study, 15 biopsy specimens were procured retrospectively from patients being treated for adenocarcinoma of the esophagus. The tissue was immunostained for the vitamin D receptor and compared on the basis of response to neoadjuvant therapy. Tumors that did not respond to neoadjuvant therapy had greater expression of VDR than tumors that responded completely. Expression of VDR declined with tumor de-differentiation. The data suggest that a relationship between vitamin D receptor expression and response to neoadjuvant therapy is plausible.

Original language	English (US)
Pages (from-to)	147-153
Number of pages	7
Journal	Experimental and Molecular Pathology
Volume	93
Issue number	1
DOIs	https://doi.org/10.1016/j.yexmp.2012.04.018
State	Published - Aug 1 2012

All Science Journal Classification (ASJC) codes

Pathology and Forensic Medicine
Molecular Biology
Clinical Biochemistry

Access to Document

10.1016/j.yexmp.2012.04.018

Fingerprint Dive into the research topics of 'Vitamin D receptor expression and neoadjuvant therapy in esophageal adenocarcinoma'. Together they form a unique fingerprint.

Cite this

@article{f6d7a90b0bca462f8936a794a140e5d1,

title = "Vitamin D receptor expression and neoadjuvant therapy in esophageal adenocarcinoma",

abstract = "Esophageal adenocarcinoma carries a poor prognosis. Tumor response to neoadjuvant therapy is a key prognostic factor in patients with adenocarcinoma of the esophagus, but is inconsistent. Identifying tumor characteristics that portend a favorable response to neoadjuvant therapy would be a valuable clinical tool. The anticancer actions of vitamin D and its receptor may have implications. In this study, 15 biopsy specimens were procured retrospectively from patients being treated for adenocarcinoma of the esophagus. The tissue was immunostained for the vitamin D receptor and compared on the basis of response to neoadjuvant therapy. Tumors that did not respond to neoadjuvant therapy had greater expression of VDR than tumors that responded completely. Expression of VDR declined with tumor de-differentiation. The data suggest that a relationship between vitamin D receptor expression and response to neoadjuvant therapy is plausible.",

author = "Ryan Trowbridge and Poonam Sharma and Hunter, {William J.} and Agrawal, {Devendra K.}",

year = "2012",

month = aug,

day = "1",

doi = "10.1016/j.yexmp.2012.04.018",

language = "English (US)",

volume = "93",

pages = "147--153",

journal = "Experimental and Molecular Pathology",

issn = "0014-4800",

publisher = "Academic Press Inc.",

number = "1",

}

TY - JOUR

T1 - Vitamin D receptor expression and neoadjuvant therapy in esophageal adenocarcinoma

AU - Trowbridge, Ryan

AU - Sharma, Poonam

AU - Hunter, William J.

AU - Agrawal, Devendra K.

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Esophageal adenocarcinoma carries a poor prognosis. Tumor response to neoadjuvant therapy is a key prognostic factor in patients with adenocarcinoma of the esophagus, but is inconsistent. Identifying tumor characteristics that portend a favorable response to neoadjuvant therapy would be a valuable clinical tool. The anticancer actions of vitamin D and its receptor may have implications. In this study, 15 biopsy specimens were procured retrospectively from patients being treated for adenocarcinoma of the esophagus. The tissue was immunostained for the vitamin D receptor and compared on the basis of response to neoadjuvant therapy. Tumors that did not respond to neoadjuvant therapy had greater expression of VDR than tumors that responded completely. Expression of VDR declined with tumor de-differentiation. The data suggest that a relationship between vitamin D receptor expression and response to neoadjuvant therapy is plausible.

AB - Esophageal adenocarcinoma carries a poor prognosis. Tumor response to neoadjuvant therapy is a key prognostic factor in patients with adenocarcinoma of the esophagus, but is inconsistent. Identifying tumor characteristics that portend a favorable response to neoadjuvant therapy would be a valuable clinical tool. The anticancer actions of vitamin D and its receptor may have implications. In this study, 15 biopsy specimens were procured retrospectively from patients being treated for adenocarcinoma of the esophagus. The tissue was immunostained for the vitamin D receptor and compared on the basis of response to neoadjuvant therapy. Tumors that did not respond to neoadjuvant therapy had greater expression of VDR than tumors that responded completely. Expression of VDR declined with tumor de-differentiation. The data suggest that a relationship between vitamin D receptor expression and response to neoadjuvant therapy is plausible.

UR - http://www.scopus.com/inward/record.url?scp=84860821724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860821724&partnerID=8YFLogxK

U2 - 10.1016/j.yexmp.2012.04.018

DO - 10.1016/j.yexmp.2012.04.018

M3 - Article

C2 - 22546272

AN - SCOPUS:84860821724

VL - 93

SP - 147

EP - 153

JO - Experimental and Molecular Pathology

JF - Experimental and Molecular Pathology

SN - 0014-4800

IS - 1

ER -